By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


QR Pharma 

259 Radnor Chester Road
Suite 205
Radnor  Pennsylvania  19087  U.S.A.
Phone: 484-253-2296 Fax: 484-253-2288



Company News
QR Pharma Begins Collaboration On Posiphen And Huntington’s Disease 2/4/2015 10:56:29 AM
QR Pharma Announces The Appointment Of New Chairman And New Board Member 1/6/2015 12:14:53 PM
QR Pharma and University of California, Los Angeles (UCLA) Awarded $3 Million US Army Grant to Test Posiphen in Rat Models of Concussion and Blunt Head Trauma 10/10/2013 9:45:05 AM
QR Pharma Release: Posiphen Restores Brain Function, Cognition and Memory in Transgenic Alzheimer Mice 10/22/2012 9:42:17 AM
QR Pharma Announces the Start of a Phase I Clinical Study for Bisnorcymserine 7/24/2012 9:59:52 AM
QR Pharma Awarded Funding by The Michael J. Fox Foundation to Test Posiphen® as a Treatment for Parkinson’s Disease 3/6/2012 8:43:16 AM
QR Pharma Reports Results from SBIR Grant by NIA/National Institutes of Health (NIH) to Study Posiphen(R) and Metabolites in Various Models 10/13/2011 10:07:10 AM
Jeffrey Cummings, Rachelle Doody, Martin Farlow and Mary Sano to Form QR Pharma’s Medical Advisory Board 2/3/2011 11:15:23 AM
QR Pharma to Present at the 44th Winter Conference on Brain Research 1/19/2011 9:10:48 AM
QR Pharma Receives FDA Clearance to Conduct Clinical Trials with Its Second Novel Alzheimer Compound, Bisnorcymserine 12/2/2010 10:41:12 AM